Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

What is a certified reference material?

Mattsson N, Zetterberg H.

Biomark Med. 2012 Aug;6(4):369-70. doi: 10.2217/bmm.12.37. No abstract available.

PMID:
22917138
2.

Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay.

Zegers I, Keller T, Schreiber W, Sheldon J, Albertini R, Blirup-Jensen S, Johnson M, Trapmann S, Emons H, Merlini G, Schimmel H.

Clin Chem. 2010 Dec;56(12):1880-8. doi: 10.1373/clinchem.2010.148809. Epub 2010 Oct 5.

3.

Development and preparation of a new serum protein reference material: feasibility studies and processing.

Zegers I, Schreiber W, Linstead S, Lammers M, McCusker M, Muñoz A, Itoh Y, Merlini G, Trapmann S, Emons H, Sheldon J, Schimmel H.

Clin Chem Lab Med. 2010 Jun;48(6):805-13. doi: 10.1515/CCLM.2010.166.

PMID:
20374041
4.

Analytical aspects of molecular Alzheimer's disease biomarkers.

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44. Review.

PMID:
22917140
6.

Biomarkers in Alzheimer's disease.

Hyman BT.

Neurobiol Aging. 1998 Mar-Apr;19(2):159-60. Review. No abstract available.

PMID:
9558154
7.

Important differences in measurement of fetuin-A.

Smith ER, Holt SG.

Ann Intern Med. 2010 Sep 21;153(6):419; author reply 419-20. doi: 10.7326/0003-4819-153-6-201009210-00016. No abstract available.

PMID:
20855811
8.

Fluid biomarkers for Alzheimer's disease: standardization and recent developments.

Zetterberg H, Visser PJ.

Biomark Med. 2012 Aug;6(4):363-4. doi: 10.2217/bmm.12.40. No abstract available.

9.

Calibration is the key to immunoassay but the ideal calibrator is unattainable.

Whicher JT.

Scand J Clin Lab Invest Suppl. 1991;205:21-32. Review.

PMID:
1947745
10.

Serum protein standardization project in Japan: evaluation of an IFCC reference material (RPPHS/CRM470) and establishment of reference intervals.

Itoh Y, Ichihara K, Kanno T, Sugawara T, Ohkubo A, Hirabayashi Y, Igarashi S, Kawano K, Iwata S, Saito K, Kawai T.

J Clin Lab Anal. 1997;11(1):39-44.

PMID:
9021523
11.
12.

Biomarkers for Alzheimer's disease. Which way to go?

Teunissen CE, Scheltens P.

Neurobiol Aging. 2004 Jul;25(6):695-6. No abstract available.

PMID:
15165690
13.

Biomarkers in Alzheimer's disease.

Lovestone S.

J Nutr Health Aging. 2006 Mar-Apr;10(2):118-22. No abstract available.

PMID:
16554945
14.

Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.

Zetterberg H, Lunn MP, Herukka SK.

Biomark Med. 2012 Aug;6(4):371-6. doi: 10.2217/bmm.12.47.

PMID:
22917139
15.

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ; National Institute on Aging Biological Markers Working Group.

Neurobiol Aging. 2003 Jul-Aug;24(4):521-36. Review. No abstract available.

PMID:
12714109
16.
17.

Wrong biochemistry results.

Ismail AA, Barth JH.

BMJ. 2001 Sep 29;323(7315):705-6. No abstract available.

18.

Alzheimer research forum live discussion: Making a BioMark on Alzheimer disease.

[No authors listed]

J Alzheimers Dis. 2005 Mar;8(4):393-9. No abstract available.

PMID:
16646143
19.

Blood-based biomarkers in Alzheimer disease: where are we now and where have we to go?

Laske C.

JAMA Neurol. 2013 Jan;70(1):133. doi: 10.1001/2013.jamaneurol.67. No abstract available.

PMID:
23318524
20.

Amyloid beta and APP as biomarkers for Alzheimer's disease.

Zetterberg H, Blennow K, Hanse E.

Exp Gerontol. 2010 Jan;45(1):23-9. doi: 10.1016/j.exger.2009.08.002. Epub 2009 Aug 19. Review.

PMID:
19698775

Supplemental Content

Support Center